Kalcipos-D Mite (Colecalciferol, Calcium)

Colecalciferol is converted to its active form, 1,25‑dihydroxyvitamin D, which binds to vitamin D receptors in the intestine. This binding stimulates the synthesis of calcium‑binding proteins, thereby increasing the absorption of calcium and phosphate from the diet, which are essential for bone formation and maintenance.

The appropriate dose of Kalcipos-D Mite is determined by a qualified prescriber based on the patient’s age, clinical condition, laboratory values, and any concomitant therapies. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for Kalcipos-D Mite in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential benefits and risks with their physician before using this product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kalcipos-D Mite combines colecalciferol with calcium in a single oral tablet, offering a convenient formulation. Compared with separate calcium carbonate and vitamin D2 products, it provides vitamin D3, which is more efficiently converted to the active hormone, and may result in more consistent absorption of calcium.

Store Kalcipos-D Mite below 25 °C in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight. Do not use the product if the packaging is damaged or if the tablets appear discolored.

Kalcipos-D Mite is taken orally with a glass of water. It can be taken with or without food, although taking it with a meal may improve tolerability for some individuals. Swallow the tablet whole; do not crush or chew it.

The most serious risks include severe hypercalcemia, which can cause cardiac arrhythmias, kidney stones, and soft‑tissue calcification, as well as rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience symptoms like excessive thirst, frequent urination, or unexplained muscle weakness.

Kalcipos-D Mite should be avoided in individuals with known hypercalcemia, severe renal impairment, or a documented hypersensitivity to colecalciferol, calcium, or any excipients in the tablet. Consultation with a healthcare professional is essential before starting therapy in these cases.